Clinical Trials Logo

Filter by:
NCT ID: NCT02921854 Completed - Clinical trials for Non Small Cell Lung Cancer

Detection of Circulating Biomarkers of Immunogenic Cell Death

ICD
Start date: April 4, 2017
Phase: N/A
Study type: Interventional

In this exploratory study, the investigators will investigate if markers (molecular and immunological) of ICD or anti-tumor immunity (exosomal or molecular) can be detected in the serum of patients after high-dose radiotherapy alone or concurrent cisplatin-doublet therapy and radiotherapy. For each patient: withdraw blood at three times during treatment for analysis.

NCT ID: NCT02920398 Completed - Clinical trials for Congenital Bleeding Disorder

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A

pathfinder™7
Start date: October 4, 2016
Phase: Phase 1
Study type: Interventional

Investigating single dose pharmacokinetics and safety of turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process in patients with severe haemophilia A

NCT ID: NCT02920294 Completed - Ileostomy - Stoma Clinical Trials

Modulation of Microbial Composition in Ileostomy Patients

INSIDE
Start date: September 2016
Phase: N/A
Study type: Interventional

To determine the small intestinal microbiota response in humans to dietary interventions for two consecutive weeks, and to relate this to parameters of intestinal barrier function and immune and metabolic responses in blood, as functional outcome parameters of host physiology

NCT ID: NCT02919579 Completed - Clinical trials for Depressive Disorder, Major

A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder

DriveSaFe2
Start date: October 7, 2016
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the effect of a single 84-milligram (mg) dose of intranasal esketamine compared to placebo, on next day driving performance and repeated administration of 84 mg intranasal esketamine on same-day driving performance as assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test.

NCT ID: NCT02919319 Completed - Healthy Subjects Clinical Trials

A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects

Start date: February 1, 2015
Phase: Phase 1
Study type: Interventional

The main objectives of this first-into-man study were to investigate the safety, tolerability and the pharmacokinetic profile of single oral doses of ACT-541468 in healthy male adults. Pharmacodynamic effects (through a battery of Central Nervous System tests) were also assessed.

NCT ID: NCT02916953 Completed - Osteoporosis Clinical Trials

CONFIRM - Study of AGN1 LOEP in Patients With Osteoporosis

Start date: December 17, 2016
Phase: N/A
Study type: Interventional

The study will evaluate the immediate procedure and post-procedure profile of the AGN1 Femoral LOEP™ Kit. All subjects will receive the treatment and be evaluated for any adverse or serious adverse events that could occur during the procedure or immediately post-procedure.

NCT ID: NCT02914665 Completed - Heart Failure Clinical Trials

A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure

Start date: October 20, 2016
Phase: Phase 2
Study type: Interventional

This is a phase 2 randomized, double-blind, placebo-controlled study to evaluate the cardiac and renal effects of short term treatment with elamipretide in patients hospitalized with congestion due to heart failure

NCT ID: NCT02914561 Completed - Crohn's Disease Clinical Trials

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

DIVERSITY1
Start date: October 31, 2016
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naive and biologic-experienced. Participants who complete the study, or do not meet protocol response or remission criteria at Week 10 will have the option to enter a separate long-term extension (LTE) study (Study GS-US-419-3896).

NCT ID: NCT02914522 Completed - Ulcerative Colitis Clinical Trials

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis

SELECTION
Start date: November 14, 2016
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in participants who are biologic-naive and biologic-experienced. Participants who complete the study, or met protocol specified efficacy discontinuation criteria will have the option to enter a separate, long-term extension (LTE) study (Gilead Study GS-US-418-3899: NCT02914535).

NCT ID: NCT02914470 Completed - Breast Cancer Clinical Trials

Carboplatin-cyclophosphamide Combined With Atezolizumab

PROLOG
Start date: January 2017
Phase: Phase 1
Study type: Interventional

This is a single centre, 3+3, dose finding, open label, phase 1b clinical study of carboplatin and cyclophosphamide, in combination with atezolizumab.